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IFN-b is induced via a c-fos dependent mechanism that is present downstream of the receptor acti-
vator of NF-jB ligand (RANKL)-RANK signal transduction cascade during osteoclast differentiation.
Increased production of IFN-b in turn inhibits osteoclastogenesis. However, the mechanism by
which IFN-b exerts its suppressive function remains unclear. In the present study, we found that
miR-155, an IFN-b-induced miRNA, mediated the suppressive effect of IFN-b on osteoclast differen-
tiation by targeting SOCS1 and MITF, two essential regulators of osteoclastogenesis. These ﬁndings
have not only demonstrated that miR-155 inhibits osteoclast differentiation, but also provided a
new therapeutic target for treatment of osteoclast-mediated diseases.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Osteoclasts are multinucleated bone-absorbing cells derived
from the monocyte-macrophage lineage under the presence of
receptor activator of NF-jB ligand (RANKL) and M-CSF [1–4].
M-CSFpromotes proliferationand survival of osteoclast progenitors.
RANKL prompts the cells to differentiate along the osteoclast linage
and acts as an activating and survival factor for mature osteoclasts
[5–6]. RANKL exerts its effect on osteoclasts by binding to the recep-
tor RNAK expressed on osteoclast precursors and mature osteo-
clasts. The interaction of RANKL and RANK results in recruitment
of the adaptor molecules such as TNF receptor-associated factors
and stimulates downstream signaling cascades, including three
well-knownMAPK pathways, PI3K, andNF-jB [7]. RANKL also leadschemical Societies. Published by E
-b; RANKL, receptor activator
acrophages; TRAP, tartrate-
cytokine signaling1; MITF,
Rs, 30untranslated regions
hopedics, Zhejiang Provincial
0014, PR China. Fax: +86 571
).to the induction of osteoclastogenic transcription factors, including
c-Fos, Fra-1 and cytoplasmic, calcineurin-dependent NFAT1
(NFATc1) [8–11].
The maintenance of bone homeostasis is dependent on the bal-
ance between bone-forming osteoblasts and bone-resorbing osteo-
clasts [12–13]. Excessive bone resorption by osteoclasts is often
associated with diseases accompanied by pathological bone loss,
including osteoporosis and rheumatoid arthritis [14–17]. Thus, re-
search into the mechanism of osteoclast differentiation is both bio-
logically and clinically important.
IFN-b plays an inhibitory role during osteoclast differentiation.
IFN-b is induced in response to osteoclast activation by RANK-
RNAKL interaction [18]. Increased production of IFN-b is in turn ex-
pected to inhibit c-fos activity resulting in the inhibition of osteo-
clastogenesis. The effects of IFN-b are primarily mediated through
Jak-Stat pathway, inhibitory effects related to osteoclastogenesis
may be regulated through the interferon stimulated gene factor 3
(ISGF3) complex comprising of signal transducers and activators
of transcription (STAT)1 and STAT2 and interferon regulatory factor
9 (IRF9) [18]. Protein kinase R (PKR) has been implicated tomediate
the inhibition of c-fos protein by IFN-b [18–19]. CXCL11may be an-
other key intermediary in the inhibition of c-fos by IFN-b [20–21].
However, the other regulators mediated the suppressive effect oflsevier B.V. All rights reserved.
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gated.microRNAs (miRNAs) are small, noncoding RNAs that are in-
volved in posttranscriptional repression by binding to minimal
binding sites on target mRNAs [22]. Many miRNAs play roles in
hematopoietic cells, including osteoclasts [23]. A speciﬁc miRNA,
miR-155, is involved in the commitment of monocyte progenitors
to macrophage differentiation and activation, by effectively inter-
fering with the genetic network driving the alternative, osteoclast
fate [24]. By targeting SOCS1, miR-155 regulates antiviral innate
immunity and dendritic cell development, controls macrophage re-
sponse to lipopolysaccharide, and acts as an oncomiRNA in breast
cancer [25–28]. Whether miR-155 also controls osteoclast differen-
tiation by targeting SOCS1 is unknown, although it is well-known
that SOCS1 facilitates osteoclastogenesis by blocking the inhibitory
effect of inﬂammatory cytokines and IFN-b on RANKL-mediated
osteoclast differentiation signals [29–30]. In monocyte lineage,
miR-155 was induced by IFN-b [28,31], playing an important role
inmonocyte proliferation, and inmacrophage and dendritic cell dif-
ferentiation [32]. However, the roles of miR-155 in the osteoclast
trajectory, derived from the same precursor, were less known.
Our data suggest that miR-155 is induced by IFN-b, and mediates
the suppressive effect of IFN-b on osteoclast differentiation by tar-
geting SOCS1 and microphthalmia-associated transcription factor
(MITF), two positive regulators during osteoclastogenesis.
2. Materials and methods
2.1. Mice
C57BL/6 mice (6–8 weeks old) were purchased from SIPPR-BK
Experimental Animal (Shanghai, China). IFNb and IFNAR1 deﬁcient
mice were from Knockout Mouse Project (KOMP) Repository and
were bred in speciﬁc pathogen-free conditions. All animal experi-
ments were undertaken in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals, with
the approval of the Scientiﬁc Investigation Board of Zhejiang Uni-
versity (Hangzhou, China).
2.2. Reagents
Mouse RANKL and M-CSF were from PeproTech (Rocky Hill, NJ).
Mouse recombinant IFN-b was from R&D (Minneapolis, MN). TLR3
ligand Poly I:C and anti-b-actin were from Sigma–Aldrich (St.
Louis, MO). Anti-Socs1 and HRP-coupled secondary Abs were from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Mitf was from
LifeSpanBioSciences (Seattle, WA). The miR-155 mimic and its con-
trol mimic were from GenePharma (Shanghai, China). The transfec-
tion reagents Jet-EndoTM and INTERFERinTM were from PolyplusFig. 1. IFN-b induced miR-155 in bone marrow-derived macrophages (BMMs). (A) BMM
(IFNb/) mice were cultured in osteoclastogenesis condition for 4 days, qPCR assays w
with indicated doses of IFN-b in osteoclastogenesis condition for 12 h. qPCR assays we
IFNb/ mice was stimulated with 10 lg/ml Poly I:C or infected with VSV (MOI = 0.1)
miR-155 expression. Data are mean ± S.E.M of three independent experiments. ⁄⁄P < 0.0Transfection (Illkirch, FRANCE). siRNAs targeting Socs1 and Mitf
were from Dharmacon (ThermoFisher Scientiﬁc, Lafayette, CO).
VSV virus (Hazelhurst strain) from was from American Type Cul-
ture Collection (ATCC) (Manassas, VA).
2.3. Cell culture and transfection
HEK293T cells andMurinemacrophage cell line RAW264.7were
obtained from the ATCC (Manassas, VA) and maintained at 37 C
(5% CO2, 95% air) in culture medium consisting of DMEM supple-
mented with 10% FBS. INTERFERinTM was used to transfect siRNAs
into RAW 264.7 cells according to the manufacturer’s instructions.
2.4. Generation of BMMs and osteoclastogenesis
Femurs and tibiae were separated from C57BL/6 mice. After
soaking the bones in 70% ethanol for 2 min and rising in PBS, both
end were cut, and the bone marrowwas ﬂushed out with PBS using
a 25-gauge syringe. Erythrocytes were lysed using M-lysis buffer
(R&D Systems, Minneapolis, MN). To prepare osteoclast precursors,
bone marrow cells were cultured in a-MEM supplemented with
10% FBS overnight. The next day, non-adherent cells were harvested
and culturedwitha-MEM supplementedwith 10% culture superna-
tant from CMG14–12 cells as the source of M-CSF. After 3 days of
culturing, ﬂoating cells were removed, and attached cells were used
as osteoclast precursor cells (BMMs). For in vitro osteoclast differ-
entiation, BMMs were cultured in 24-well plates (5  104 cells/
well) in a-MEM in the presence of M-CSF and RANKL for 4 days
and stained for tartrate-resistant acid phosphatase (TRAP) activity
using a leukocyte acid phosphatase kit (Sigma–Aldrich, St.Louis,
MO). In osteoclastogenesis condition, the concentration of M-CSF
and RANKL is 50 ng/ml and 100 ng/ml, respectively.
2.5. RNA quantiﬁcation
Total RNAwas extractedwith TRIzol reagent (Invitrogen) accord-
ing to the manufacturer’s instructions. Real-time quantitative RT-
PCR analysis was performed using the LightCycler (Roche) and SYBR
RT-PCR kits (Takara). The relative expression level of miRNAs was
normalized to the internal control U6 by using 2DDCt cycle thresh-
oldmethod [33]. The relative expression level of Socs1 andMitf was
normalized to the level of b-actin expression in each sample.
2.6. Plasmid construction
The Socs1 30UTR and Mitf 30UTR luciferase reporter constructs
were made by amplifying the mouse Socs1 30UTR and Mitf 30UTR
sequence by PCR and cloning into the MluI and Spe I sites ofs from wild type (wt) mice, IFNAR1 deﬁcient (IFNAR1/) mice or IFNb deﬁcient
ere performed to detect the miR-155 expression.(B) Wild type BMMs were treated
re performed to detect the miR-155 expression. (C) BMMs from wt, IFNAR1/ or
in osteoclastogenesis condition for 24 h, qPCR assays were performed to detect the
1.
Fig. 2. miR-155 mediated the suppressive effect of IFN-b on osteoclast differentiation. (A–B) BMMs fromwt, IFNAR1/ or IFNb/mice were cultured in osteoclastogenesis
condition for 4 days. TRAP-positive multinucleated cells were counted as osteoclasts. (C) BMMs were incubated for 8 h with the pBABE, pBABE-155 or pBABE-155s viral
supernatants in the presence of M-CSF (50 ng/ml) and polybrene (6 lg/ml). After the viral supernatant was removed, BMMs were further cultured in osteoclastogenesis
condition for 24 h. qPCR assays were performed to detect the miR-155 expression. (D) HEK293T cells were cotransfected with pTK-Renilla luciferase plasmids, Socs1 30UTR
reporter construct and indicated retroviral construct, 24 h later, the ﬁreﬂy luciferase activity was measured and normalized to Renilla luciferase activity. (E–H) wild type,
IFNAR1/ or IFNb/ BMMs were incubated for with the pBABE, pBABE-155 or pBABE-155s viral supernatants as described in (C). After the viral supernatant was removed,
BMMs were further cultured in osteoclastogenesis condition with or without IFN-b for 4 days. TRAP-positive multinucleated cells were counted as osteoclasts. Data of (A), (C),
(E) and (G) are mean ± S.E.M of three independent experiments. Data of C is mean ± SD (n = 6) of one representative experiment. Similar results were observed in three
independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01.
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30UTR luciferase reporter constructs were generated by converting
miR-155 binding site ‘‘AGCATTAA’’ into ‘‘ACCTTAAT’’.
2.7. Statistical analysis
Statistical signiﬁcance was determined by Student0s t test, with
P values of 50.05 considered to be statistically signiﬁcant.
3. Results
3.1. IFN-b induced miR-155 during osteoclastogenesis
IFN-b negatively regulates the osteoclast differentiation, which
is an important regulatory mechanism for bone homeostasis [18].
miR-155 suppresses the RANKL-induced osteoclast differentiation
by repressing the expression of MITF, a transcription factor essen-
tial for osteoclast differentiation [24]. It also has been reported that
miR-155 is induced in primary murine macrophages after exposure
to the cytokine IFN-b [31]. After culturing the bonemarrow-derived
macrophages (BMMs) in the presence of M-CSF and RANKL for
4 days, the BMMs were differentiated into tartrate-resistant acid
phosphatase (TRAP) positive osteoclasts. The wild type osteoclastsFig. 3. Socs1 and Mitf were potential targets of miR-155. (A) The seed region of miR-15
very conserved among mammals. (B) The seed region of miR-155 was complementary to
Two potential sites in mouse Mitf 30UTR could be targeted by miR-155. (D) HEK293T
luciferase reporter plasmids, 10 ng pTK-Renilla luciferase plasmids, together with contro
24 h, ﬁreﬂy luciferase activity was measured and normalized to Renilla luciferase activity.
(mutant #1) Mitf 30UTR was cotransfected with pTK-Renilla and miRNAmimics, and then
(n = 6) of one representative experiment. Similar results were observed in three indepenexpressed much more miR-155 than the IFNAR1/ or IFNb/
osteoclasts (Fig. 1A). To determine if IFN-b could induce miR-155
during osteoclast differentiation, we added increasing dose of
IFN-b in osteoclastogenesis conditions. Increasing miR-155 induc-
tion could be observed after treating with increasing doses of IFN-
b (Fig. 1B). Given that TLR3-triggered and VSV-infected macro-
phages produce large amount of IFN-b [34–35]. We stimulated
the BMMs with poly I:C or infected with VSV during osteoclast dif-
ferentiation. The IFNAR1/ and IFNb/ BMMs expressed less
miR-155 than wild type BMMs, no matter stimulated with poly
I:C or infected with VSV (Fig. 1C). Taken together, induction of
miR-155 was IFN-b dependent during osteoclast differentiation.
3.2. miR-155 suppressed osteoclast differentiation
IFN-b inhibits osteoclast differentiation and induction of miR-
155 was IFN-b dependent. Therefore, we hypothesized that miR-
155 mediated the suppressive effect of IFN-b on osteoclastogene-
sis. Consistent with the reported data [18], we found that
IFNAR1/ and IFNb/ BMMs could differentiate into more
osteoclasts than the wild type BMMs (Fig. 2A and B). In order to
overexpress miR-155 in BMMs, we constructed pBABE-155 by
inserting part of the primary mir-155 into pBABE vector, a5 was well complementary to SOCS1 30UTR. The binding sites in SOCS1 30UTR were
MITF 30UTR. The binding sites in MITF 30UTR were conserved among mammals. (C)
cells were cotransfected with 80 ng wild type (wt) or mutant Socs1 30UTR ﬁreﬂy
l (Ctrl) mimics or miR-155 mimics, (ﬁnal concentration: 20nM) as indicated. After
(E) Wild type (wt) or the double mutant (mutant #1 + #2) or the position #1 mutant
the relative luciferase activity was measured as described in (D). Data are mean ± SD
dent experiments. ⁄⁄P < 0.01.
Fig. 4. miR-155 inhibited Socs1 and Mitf expression during osteoclast differentiation. (A–C) wild type BMMs were incubated in the presence of M-CSF (50 ng/ml) with or
without RANKL (100 ng/ml) for 24 h, Socs1 and Mitf expression were detected by qPCR (A–B) and Western blot (C). (D–G) wild type BMMs were incubated for 8 h with the
pBABE, pBABE-155 or pBABE-155s viral supernatants in the presence of M-CSF (50 ng/ml) and polybrene (6 lg/ml). After the viral supernatant was removed, BMMs were
further cultured in osteoclastogenesis condition for 4 days. The Socs1 and Mitf mRNA expression were detected by qPCR (D–E) and protein expression were detected by
Western blot (F–G). Data of (A), (B) and (D) are mean ± S.E.M of three independent experiments, ⁄⁄P < 0.01. Data of (C), (F) and (G) are shown as one representative
experiment. Similar results were observed in three independent experiments.
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miR-155, we constructed pBABE-155s by inserting 7 repeats of
miR-155 sponge sequence into pBABE vector. A robust upregula-
tion of miR-155 in pBABE-155-tranduced BMMs, while no signiﬁ-
cant downregulation of miR-155 in pBABE-155s-transduced
BMMs (Fig. 2C). It was reported that miRNA sponge absorbed
endogenous miRNA rather than degrading them [36], and Socs1
is one of the miR-155 targets [25–28]. We found that increasing
the luciferase activity of Socs1 30UTR reporter could be found after
transfecting with increasing dose of pBABE-155s vectors into
HEK293T cells (Fig. 2D). Therefore, pBABE-155s could inhibit the
function of endogenous miR-155. We transduced BMMs with pBA-
BE-155 or pBABE-155s retroviruses, and then cultured those BMMs
in osteoclastogenesis condition. pBABE-155 suppressed osteoclasts
differentiation while pBABE-155s facilitated it. After adding IFN-b
into the osteoclastogenesis condition, the osteoclast differentiation
was suppressed signiﬁcantly, the suppression of pBABE-155 was
abolished. However, pBABE-155s could slightly reverse the sup-
pressive effect of IFN-b on osteoclast differentiation (Fig. 2E and
F). We found similar results in IFNAR1/ and IFNb/ BMMs
as wild type BMMs (Fig. 2G and H). That was to say, pBABE-155could suppress osteoclasts differentiation while pBABE-155s facil-
itate it without the activation of IFNAR-Jak-Stat signaling. In con-
clusion, miR-155 could suppress osteoclast differentiation and
mediate the suppressive effect of IFN-b on osteoclastogenesis.
3.3. Socs1 and Mitf were potential targets of miR-155
By using bioinformatic tools for miRNA target prediction (Tar-
getscan [http://www.targetscan.org] and miRanada [http://
www.microrna.org]), we found that there were miR-155 binding
sites in the 30UTRs of SOCS1 and MITF. The miR-155 binding site
in SOCS1 30UTR was highly conserved in mammals (Fig. 3A).
Although the miR-155 binding site in MITF 30UTR was not so highly
conserved in mammals as SOCS1 30UTR (Fig. 3B), MITF was re-
ported as a target of miR-155 [24]. There were two potential
miR-155 binding sites in mouse Mitf 30UTR and the position #1
was more complementary to the seed region of miR-155
(Fig. 3C). miR-155 inhibited the luciferase activity of wild type
Socs1 30UTR reporter while has no effect on mutant Socs1 30UTR re-
porter in which the miR-155 binding site was mutated (Fig. 3D).
Similarly, miR-155 inhibited the luciferase activity of wild type
Fig. 5. Socs1 and Mitf facilitated osteoclast differentiation. (A–D) wild type BMMs were transfected with Socs1 siRNA (si-Socs1) or their control siRNA (Ctrl) for 8 h, then the
cells were incubated in osteoclastogenesis condition for 4 days, the Socs1 expression were detected by qPCR (A) and Western blot (B). TRAP-positive multinucleated cells
were counted as osteoclasts (C–D). (E–H) Calcitonin receptor (E), V-Atpase d2 (F), TRAP (G) and Cathepsin K (H) mRNA from cells described in (A–D) were detected by qPCR.
(I–L) wild type BMMs were transfected with Mitf siRNA (si-Socs1) or their control siRNA (Ctrl) for 8 h, then the cells were incubated in osteoclastogenesis condition for 4 days,
the Mitf expression were detected by qPCR (I) and Western blot (J). TRAP-positive multinucleated cells were counted as osteoclasts (K–L). (M–P) Calcitonin receptor (M), V-
Atpase d2 (N), TRAP (O) and Cathepsin K (P) mRNA from cells described in I–L were detected by qPCR. The western blot data are shown as one representative experiment. The
qPCR and TRAP-positive osteoclast data are mean ± S.E.M of three independent experiments, ⁄⁄P < 0.01.
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reporters in which both miR-155 binding sites or only position
#1 binding site was mutated (Fig. 3E). According to the results of
Mitf 30UTR reporter, it seemed that position #1 binding site could
be targeted by miR-155, although it was not perfectly complemen-
tary to the seed region of miR-155.
3.4. miR-155 inhibited Socs1 and Mitf expression during osteoclast
differentiation
To address whether miR-155 regulates Socs1 and Mitf expres-
sion during osteoclast differentiation. First, we detected the Socs1
and Mitf expression from BMMs after one day treated with or
without RANKL. Signiﬁcant induction of both Socs1 and Mitf wasfound in RANKL-treated groups (Fig. 4A–C). Next, we infected
BMMs with pBABE-155 or pBABE-155s retrovirus. After one day
culturing in osteoclastogenesis condition, pBABE-155 suppressed
Socs1 and Mitf expression while pBABE-155s facilitated their
expression (Fig. 4D-G). Our data indicated that miR-155 could tar-
get Socs1 and Mitf during osteoclastogenesis, therefore, miR-155
might inhibit osteoclast differentiation by targeting Socs1 and Mitf,
thus at least partially mediate the suppressive effect of IFN-b on
osteoclastogenesis.
3.5. Socs1 and Mitf facilitated osteoclast differentiation
To further determine the roles of miR-155 in the regulation of
osteoclast differentiation. We used siRNAs to interfere with the
Fig. 6. miR-155 was involved in the signaling networks of osteoclast differentiation.
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Socs1 could downregulate Socs1 expression during osteoclast dif-
ferentiation, both in mRNA level and protein level (Fig. 5A and
B). The osteoclast differentiation was also inhibited after silencing
the endogenous Socs1 (Fig. 5C and D). Meanwhile, we found that
several osteoclast marker genes such as Calcitonin receptor, V-Atp-
ase d2, TRAP and Cathepsin K were downregulated after knocking
down Socs1 (Fig. 5E-H). Similarly, we found that osteoclast differ-
entiation was suppressed and osteoclast marker genes were down-
regulated after knocking down Mitf (Fig. 5I–P). The above data not
only proved Socs1 and Mitf were positive regulators of osteoclast
differentiation, but also implied miR-155 could regulate osteoclast
differentiation by targeting Socs1 and Mitf. M-CSF and osteoblast
provide signals that lead to expression of several essential tran-
scription factors in osteoclastogenesis, such AP-1, Fos and NFATc1.
These transcription factors drive the expression of their down-
stream genes and activate the differentiation of progenitor cells
into osteoclast precursor. Meanwhile, Fos-dependent IFN-b nega-
tively regulates the osteoclastogenesis via the IFN-stimulated
genes such as PKR [18–19]. IFN-b also induced miR-155, which
inhibited osteoclast differentiation by targeting SOCS1 and MITF,
two positive regulators induced by RNAKL and M-CSF and play
important roles in osteoclastogenesis (Fig. 6).
4. Discussion
IFNs exert their antiviral, antitumor or immune-regulatory
functions by inducing downstream interferon stimulated genes
via JAK-STAT pathways. However, the expression levels of some
nod-coding RNAs such as miRNAs are also changed after IFNs treat-
ment, and then those miRNAs may convey the effects of IFNs. For
instances, IFN-b-treated hepatocytes rapidly modulate the expres-
sion of numerous cellular miRNAs which have sequence-predicted
targets within the hepatitis C virus genomic RNA. The introduction
of synthetic miRNA-mimics corresponding to those IFN-b-induced
miRNAs reproduces the antiviral effects of IFN-b on HCV replica-
tion and infection [37]. Previous studies have shown that miR-
155 was induced by IFN-b and IFN-b suppressed osteoclast differ-
entiation [18,24], our present results have indicated that miR-155
mediated the suppressive effect of IFN-b on osteoclast differentia-
tion. However, lots of other miRNAs are also responsive to IFN-b
stimulation according to our unpublished microarray data,whether other IFN-b-responsive miRNAs involve in osteoclasto-
genesis still need to be investigated.
SOCS1 and MITF promote osteoclast differentiation by inhibit-
ing IFN-b downstream signaling [29–30] and cooperating with
NFATc1 [38–39], respectively. However, in order to maintain prop-
er osteoclast numbers and avoid osteoclast-mediated diseases,
negative regulation of osteoclast differentiation is also necessary.
In the present study, we have demonstrated that miR-155, an
IFN-b inducible miRNA, could target SOCS1 and MITF to convey
the suppressive effect of IFN-b on osteoclastogenesis. Considering
that SOCS1 and MITF are also responsive to IFN-b, therefore, IFN-
b-inducible miRNAs modulate the expression of IFN-b-responsive
genes, which indicates that miRNAs act as ﬁne modulators to
maintain bone homeostasis. Several interferon stimulated genes
have been reported to control the osteoclast differentiation [19–
21]. Our study has added miR-155, which is induced by IFN-b, as
a new member involved in osteoclastogenesis.
An endotoxin-induced model of inﬂammatory bone destruction
was applied to assess the in vivo efﬁciency of IFN-b for the suppres-
sion of osteoclast-mediated pathological conditions. It was indi-
cated that daily administration of IFN-b into the inﬂamed site had
markedly inhibited osteoclast formation and bone resorption,
which suggested that IFN-b indeed had a beneﬁcial effect against
bone destruction, most likely by downregulating osteoclastogene-
sis [40]. However, the prospect of using IFN-b for treatment of bone
disorders is still in its nascent stage of development. Given that the
important roles of miR-155 in inﬂammatory response regulation,
RyanM. O0Connel and his colleagues are developingmiR-155-based
drugs to treat autoimmune inﬂammation [32]. Considering the sup-
pressive effect of miR-155 on osteoclastogenesis and the advanta-
ges of miRNA-based drugs, using miR-155-based drugs is an
alternative way for treatment of the osteoclast-mediated diseases.
Although both our results and the previous report have indi-
cated miR-155 inhibits osteoclast differentiation in vitro [24], the
systemic roles of miR-155 in bone remodeling are unknown. Given
that miR-155 plays important roles in immune systems and the
miR-155 knockout mice are available [41], the roles of miR-155 in
osteoclastogeneis in vivo should be determined in further studies.
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